Navigation Links
Vion Reports 2008 Third Quarter and Nine-Month Results
Date:11/3/2008

as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210

VION PHARMACEUTICALS, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

(In thousands, except

per share data) 2008 2007 2008 2007

Technology license fee

revenue $8 $6 $35 $16

Operating expenses:

Clinical trials 2,060 3,490 7,867 10,781

Other research and

development 1,620 2,786 5,892 7,898

Total research and

development 3,680 6,276 13,759 18,679

Marketing, general and

administrative 1,872 2,279 5,655 6,387

Total operating expenses 5,552 8,555 19,414 25,066

Loss from operations (5,544) (8,549) (19,379) (25,050)

Interest income 224 938
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
2. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
3. NxStage Reports Third Quarter 2008 Financial Results
4. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
5. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Claimsnet.com Reports Third Quarter 2008 Results
10. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
11. Palomar Medical Reports Financial Results for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Dec. 4 In the midst of a ... in the United States,healthcare providers from across the ... headquarters in Redmond, Wash., for the first U.S.,Public ... to apply information technology (IT) innovations to solve ...
... Dec. 4 /PRNewswire-Asia-FirstCall/ -- Dozens of pre-screened,Greater China ... high note meeting top buyers,at Global Sources, (Nasdaq: ... http://www.PrivateSourcingEvents.com ) for sanitaryware & plumbing; ... toys; sporting,goods; and health & personal care products. ...
... having children feel responsible for the stored, frozen embryos ... are against implanting the embryos in anyone else, according ... Medical Center. , "This really turns our ... MD, an obstetrician/gynecologist and bioethicist at Duke, and lead ...
... gantry approach to coronary CT angiography reduced radiation exposure ... Thomas Jefferson University researchers. , Ethan Halpern, M.D., associate ... Jefferson University in Philadelphia, presented the research at the ... Society of North America. , "Radiation dose to the ...
... 3 ThermoGenesis,Corp. (Nasdaq: KOOL ), a ... store adult stem cells, said today that the call ... to discuss its announcement,regarding a management transition at the ... ThermoGenesis. , The ...
... for Fair and Affordable,Insurance Reform (CFAIR) is pleased to ... the need for individual insurance,market reform. , ... legislators, Ken Matzick, President and Chief,Executive Officer of Beaumont ... regulatory structure for individual health,insurance is in need of ...
Cached Medicine News:Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4Health News:Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources' Private Sourcing Events 2Health News:Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources' Private Sourcing Events 3Health News:Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources' Private Sourcing Events 4Health News:Largest study of fertility patients shows concerns about embryo disposition 2Health News:Largest study of fertility patients shows concerns about embryo disposition 3Health News:ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition 2Health News:Over 40 Hospitals Lend Support for Individual Insurance Market Reform 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Sept. 3 Forest Laboratories, Inc.,(NYSE: ... announced results from,two global Phase III studies ... for the treatment of patients with chronic,obstructive ... I&II,(AClidinium CLinical Trial Assessing Efficacy and Safety ...
... Efficacy ... Endpoints, Company to Host Conference Call and Webcast Wednesday, September ... 8:30 am ET ... NBIX ) today announced positive safety and efficacy results,from its third Phase II clinical ...
Cached Medicine Technology:Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops without Delivery System with POLYSORB™....
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: